<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-37324</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Hikma expansion</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">- Demonstration Effect: Hikma will bring in high quality manufacturing in emerging markets.
- High quality and affordable pharmaceutical products in MENA and other emerging markets.
- The investment will generate direct employment for skilled labor in addition to potential for indirect employment</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }          Hikma Pharmaceuticals PLC (Hikma or the Company) and its subsidiaries (the Group), is a generic pharmaceutical company incorporated in United Kingdom(UK)and listed on the London Stock Exchange (LSE). While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (MENA) region, the United States (US) and Europe. The Company has 29 manufacturing facilities in 11 countries out of which facilities in 5 countries have received US Food and Drug Administration (FDA) approval    . Hikmas main business   lines   include branded, injectables and generic pharmaceuticals. Hikma is a long-standing IFC client since 1987.      The Company has invited IFC to provide and arrange financing to support the general corporate purposes of the   Company   and members of its Group in the MENA region and/or in other World Bank Group countries of operation.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-37324" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2017-12-21" type="1"></activity-date>
  <activity-date iso-date="2020-04-28" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Hikma Pharmaceuticals PLC  Ibrahim Armouti  Group Treasurer  +962 6 5802900  IArmouti@Hikma.com  P.O. Box: 182400, Amman 11118, Jordan  http://www.hikma.com</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Hikma will make relevant documentation available in Arabic and/or English on its website ( www.hikma.com ) and at each of its offices in the Jordan and London. Locations and contact information for Hikma facilities may be found at  www.hikma.com .       &#xA0;      Additional enquiries should be directed to:       &#xA0;      Susan Ringdal     Investor Relations Director    Hikma Pharmaceuticals PLC    1 New Burlington Place,     London,     W1S 2HR,    United Kingdom.    Tel: +44 (0) 20 7399 2760     Fax: +44 (0) 20 7399 2761     &#xA0;    Ibrahim Armouti Group Treasurer    Hikma Pharmaceuticals PLC    P.O. Box: 182400, Amman 11118, Jordan    Tel 962 6 5802900     Fax 962 6 5827107     Email:IArmouti@Hikma.com</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="JO" percentage="100">
   <narrative xml:lang="EN">Jordan</narrative>
  </recipient-country>
  <location ref="JO-Jordan">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }  The proposed IFC funding would support Hikmas operations in the MENA region and/or other countries of World Bank Group operation.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>31.0000000000 36.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector code="325" percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">G-FA - Pharmaceuticals and Medicine Manufacturing</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $150.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2017-12-21"></period-start>
   <period-end iso-date="2018-06-30"></period-end>
   <value currency="USD" value-date="2017-12-21">150000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-12-21"></transaction-date>
   <value currency="USD" value-date="2017-12-21">150000000</value>
   <receiver-org>
    <narrative xml:lang="EN">HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetailSII/37324">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetailSII/37324">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
